entertainment -WSS

entertainment

author：knowledge 2025-10-02 01:07:15 - browse：5

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Medicare bonuses could stop drug shortages under Senate plan

focus

WSS

Maisha Meds is a PBM, but don't call it that

Medicare drug price lawsuits could be good politics for Biden

Mass General, Mayo Clinic look to monetize custom

Flu vaccine reformulation won't be easy, manufacturers warn

Medicare drug price lawsuits could be good politics for Biden

Microsoft launches AI tool for clinical documentation through Epic

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Immunocompromised patients offer clues on chronic Covid

Virginia high school admissions case could be legal follow

Dog Aging Project founders on what lies ahead after losing funding

Dobbs anniversary: the lost opportunity of abortion as health care

There's an unseen cost to disruptive road

ChatGPT in medicine: STAT answers readers' burning questions

FDA endorses new sterilization method for medical devices

Psychedelics group wrestles with new pharma identity

Dog Aging Project founders on what lies ahead after losing funding

Wikipedia

Future doctors need a strong humanities education

Pumping milk in bathrooms at health conferences is common

Printout prescription drug information shouldn’t go digital

There's an unseen cost to disruptive road

High breast density mammograms need follow

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

explore

knowledge

focus

hotspot